Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 111M | 92M | 84M | 73M | 63M |
| Gross Profit | 67M | 55M | 46M | 39M | 34M |
| Operating Income | 4M | -8M | -4M | -4M | -651K |
| EBITDA | 2M | -2M | -3M | -2M | 628K |
| Net Income | -3M | -12M | -8M | -4M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.45
+0.00% today
1Y Change
+7.14%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SomnoMed Limited (SOMNF) is a Healthcare stock with a market cap of $120.00M and listed on OTC. The stock last traded around $0.45 and up 7.1% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +21.6%, EPS growth of +83.7%, a dividend yield of 0.0%. What stands out right now is revenue +21.6%, EPS +83.7%, free cash flow +169.5% with operating margin 2.4% and ROIC 4.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SOMNF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SOMNF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SOMNF Max Drawdown
-11.76%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SOMNF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$62.7M
-13.6% YoY
FY Net Income
-$1.2M
+73.1% YoY
Free Cash Flow
-$1.4M
+79.4% YoY
Revenue Growth
+21.6%
EPS Growth
+83.7%
Gross Margin
57.4%
Net Margin
-2.2%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 111M | 92M | 84M | 73M | 63M |
| Gross Profit | 67M | 55M | 46M | 39M | 34M |
| Operating Income | 4M | -8M | -4M | -4M | -651K |
| EBITDA | 2M | -2M | -3M | -2M | 628K |
| Net Income | -3M | -12M | -8M | -4M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 17M | 16M | 12M | 16M | 21M |
| Total Assets | 81M | 70M | 62M | 58M | 56M |
| Total Liabilities | 35M | 25M | 40M | 30M | 24M |
| Shareholder Equity | 46M | 45M | 22M | 28M | 32M |
| Total Debt | 8M | 7M | 24M | 12M | 9M |
| Net Debt | -9M | -9M | 12M | -4M | -12M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+45.7% YoY
Capital Expenditures
4M
+53.0% YoY
Free Cash Flow
1M
+79.4% YoY
Key ratios
Gross Margin
57.4%
Operating Margin
2.4%
Net Margin
-2.2%
ROE
-5.3%
Debt / Equity
0.28x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.